|
Partnering Events:
|
 |
 |
 |
2008 Symposium on
Nanotechnology for Cancer Prevention, Diagnosis and Treatment
CancerNano 2008
June 1 - 5, 2008
Hynes Convention Center
Boston, Massachusetts, U.S.A
Symposium sponsors
Symposium Chairs |
|
Mansoor Amiji
Department of Pharmaceutical Sciences,
Northeastern University
|
|
|
Confirmed Invited Speakers |
|
Mark N. Milton
Vice President of Nonclinical Development
Tempo Pharmaceuticals
|
|
Cancer Gene Therapy Using Nanoparticle Vectors
Jack A. Roth
The University of Texas M. D. Anderson Cancer Center
|
|
Nanotechnology Applied to Clinical Biomarker Medicine
Lance Liotta
George Mason University
|
|
Magnetic Nanoparticles for Thermal Therapy
P. Jack Hoopes
Dartmouth Medical Center, Hanover, NH
|
|
Multifunctional Nanocarriers for Cancer Therapy
Vladimir Torchilin
Northeastern University
|
|
Molecular Imaging in Cancer
Anna Moore
Massachusetts General Hospital/Harvard Medical School
|
|
|
Folate-Targeted Nanoparticle Therapies for Cancer
Philip S. Low
Purdue University
|
|
Nanotechnology: A Key Enabler of Personalized Medicine
Linda K. Molnar,
Program Officer
Office of Technology and Industrial Relations,
National Cancer Institute
|
|
Integrated Nanoplatforms for Cancer Detection
Scott R. Manalis
Massachusetts Institute of Technology
|
|
Nanocarriers for Tumor-Targeted Drug Delivery
Tamara Minko
Rutgers University |
|
Clinical Translation of Nanotechnology for Cancer: The NCI Alliance’s Perspective
Piotr Grodzinski
NCI/NIH
|
|
|
Nanocell Delivery System for Combination Cancer Therap
Mark N. Milton
Tempo Pharmaceuticals, Cambridge, MA
|
|
Symposium Sessions |
| | Monday June 2 |
| 1:30 | Cancer Diagnosis, Imaging and Treatment - 1 |
| | Tuesday June 3 |
| 8:30 | Cancer Diagnosis, Imaging and Treatment - 2 |
| | Drug Delivery & Theraputics |
| | Merck Innovation Symposium: siRNA Delivery |
| | Phage Nanobiotechnology |
| 3:30 | Merck Innovation Symposium: siRNA Delivery |
| | Wednesday June 4 |
| 8:30 | Nanotechnology for Cancer Prevention, Diagnosis and Treatment |
| 10:30 | Nanotechnology for Cancer Prevention, Diagnosis and Treatment |
| 1:30 | Nanotechnology for Cancer Prevention, Diagnosis and Treatment |
| 3:30 | Nanotechnology for Cancer Prevention, Diagnosis and Treatment |
| | Thursday June 5 |
| 10:30 | Drug and Gene Delivery Systems |
| |
Symposium Program |
| | Monday June 2 |
| Back to Top |
| 1:30 |
Cancer Diagnosis, Imaging and Treatment - 1 | Room 208 |
| | Session chair: Linda Molnar, National Institutes of Health, US |
| 1:30 |
Nanomedicine: Engineering of a Tri-Imageable Nanoparticle for Cancer Diagnostics A. Bumb, PJ. Dobson, L. Fugger, P. Choyke, MW. Brechbiel, National Cancer Institute/University of Oxford, US |
| 1:50 |
Gold Nano-Probes as Targeted CT Contrast Agents for In-vivo cancer Imaging R. Popovtzer, A. Agrawal, M. Shlomi, A. Popovtzer, J. Balter, T.E. Carey, R. Kopelman, University of Michigan, US |
| 2:10 |
Electrokinetic Separation and Detection of DNA Nanoparticles and Cancer BioMarkers M.J. Heller, R. Krishnan, B. Sullivan, R. Mifflin, S. Esener, University of California, San Diego, US |
| 2:30 |
Development of EGFR-based Glioblastoma Targeting Imaging Agents U. Trojahn, Z. Zhang, U. Iqbal, M. Jaramillo, J. Baardsnes, A. Abedelnasser, J. Zhang, R. MacKenzie, D. Stanimirovic, T. Veres, B. Tomanek, M. O’Connor-McCourt, McGill University, CA |
| | Tuesday June 3 |
| Back to Top |
| 8:30 |
Cancer Diagnosis, Imaging and Treatment - 2 | Room 208 |
| | Session chair: J. Manuel Perez, University of Central Florida, US |
| 8:30 |
Nanotechnology: A Key Enabler of Personalized Medicine L. Molnar, National Institutes of Health, US |
| 9:00 |
Strategies for enhanced brain tumor accumulation of magnetic nanoparticles for potential drug delivery B. Chertok, A.E. David, V.C. Yang, University of Michigan, US |
| 9:20 |
5-aminolevulinic Acid Conjugated Gold Nanoparticles for Cancer Treatment M.K. Khaing Oo, X. Yang, H. Wang, H. Du, Stevens Institute of Technology, US |
| 9:40 |
Multiwalled Carbon Nanotube-Doxorubicin Supramolecular Complexes for Cancer Therapeutics H. Ali-Boucetta, K.T. Al-Jamal, K. Kostarelos, The School of Pharmacy, University of London, UK |
| Back to Top |
|
Drug Delivery & Theraputics | Exhibit Hall C |
| - |
Utility of Customized Targeted PEG Linkers for the delivery of oligonucleotides without the use of transfection reagents H. Zhao, P. Reddy, J. Xia, M. Wang, P. Sapra, R. Bandaru, M. Belen Rubio, D. Wu, P. Zhu, D. Filpula, L.M. Greenberger, I.D. Horak, Enzon Pharmaceuticals, Inc., US |
| - |
Nanoparticles of the Thermo-mechanically Activated Zeolite in the Design and Synthesis of New Drugs Generation S. Ivkovic, D. Brezak, MEGAMIN GmbH, DE |
| - |
Invention of Polysaccharide-base Nanoparticles for Enhancing Drug Permeability across the Blood Brain Barrier E.S. Gil, T.L. Lowe, Pennsylvania State University, US |
| - |
Molecular Imaging by Nanoparticle Bacterial delivery Systems: R. Sharma, University of North Carolina, Greensboro, US |
| - |
Influence of water-soluble polymers and surfactants, on mebendazole solubilization by _- and permethyl-_-cyclodextrins O-M. Ba, M. Lahiani-Skiba, S. Joudieh, F. Bounoure, M. Skiba, Université de Rouen, FR |
| - |
Synthesis of magnetic nanoparticles and its applications in drug delivery systems N. Wright Bolden, V. Rangari, S. Jeelani, Tuskegee University, US |
| - |
Organisation of peptide ligands on the surface of gene vectors M. Wang, A.D. Miller, M. Thanou, Imperial College London, UK |
| - |
Micellar form of novel poorly soluble pro-apoptotic agent, N-([(2-hydroxy-5-nitrophenyl) amino] carbonothioyl}-3, 5-dimethylbenzamide (PIT) for effective targeting to solid tumors I. Skidan, A. Degterev, P. Dholakia, V. Torchilin, Northeastern University, US |
| - |
TATp-bearing Immunoliposomes for In Vivo Gene Delivery to Ischemic Myocardium Y.T. Ko, W.C. Hartner, A. Kale, V.P. Torchilin, Northeastern University, US |
| - |
Radiolabelled Microspheres As a Delivery System For Targetad Radiotherapy G.P. Bandopadhyaya, J. Shukla, All India Institute of Medical Sciences, IN |
| - |
Lyceum Chinense and Calcium Phosphate Nanoparticles for Ophthalmic Drug Delivery Q. He, Z. Fang, M. Wang, Q.W. Xu, R. Chen, X.Z. Zhang, W.M. Yaun, D.M. Zhau, Jian Wu, Morehouse School of Medicine, US |
| - |
Long-circulating PEGylated PLGA nanoparticles for Drug Delivery J. Park, P.M. Fong, K.S. Russell, W.M. Saltzman, T.M. Fahmy, Carigent Therapeutics, US |
| - |
Encapsulation and Extended release of Anti-cancer Anastrozole by Stealth Nanoparticles K. Sarkar, H. Yang, Virginia Commonwealth University, US |
| - |
How much advantage do Nanoscale Phenomena afford for Pulmonary Delivery? N. Walji, M. Thanou, N. Quirke, Imperial College London, UK |
| - |
Evaluation of the paromomycin loading characteristics in nanoprecipitated PLGA nanospheres S. Kalimouttou, M. Lahiani-Skiba, N. Naouli, V.S. LIN, M. Skiba, Université de Rouen, FR |
| - |
Preparation And Evaluation Of In Vitro Release Of Amphiphilic _-Cyclodextrin Or Pla Nanospheres Containing A Hydrophobic Drug S. Lin, M. Lahiani-Skiba, N. Naouli, M. Skiba, Université de Rouen, FR |
| - |
Step and Flash Imprint Lithography for the Fabrication of Shape-specific, Enzymatically-triggered, Drug Nanocarriers M. Caldorera-Moore, L.C. Glangchai, L. Shi, K. Roy, The University of Texas at Austin, US |
| - |
Layer-By-Layer Formation of Polymer Micro Capsules for Drug Delivery Application A. Manju, K. Sreenivasan, Sree Chiotra Tirunal Institute for Medical Sciences and Technology, IN |
| - |
DNA-Associated Single-walled Carbon Nanotubes as a Platform for Drug Delivery B.D. Dolash, R.R. Lahiji, D.Y. Zemlyanov, R. Reifenberger, D.E. Bergstrom, Purdue University, US |
| - |
Manufacture and in vitro efficacy of lymphoma-targeted doxorubicin-loaded PLGA nanoparticles J. Lu, M. Nkansah, J. Park, P.M. Fong, Carigent Therapeutics, Inc., US |
| - |
High Fidelity Hompolymer Sequencing S. Goel, P. Griffin, R.W. Davis, M. Ronaghi, Stanford University, US |
| - |
Studies of conformational changes induced in a carrier protein: Bovine serum albumin N. El Kadi, N. Taulier, W. Urbach, M. Waks, Paris V, FR |
| - |
Real-time Detection and Quantitation of siRNAs in vivo A. Cheng, Y. Liang, A. Vlassov, M. Li, Y. Wang, L. Wong, C. Chen, S. Magdaleno, Ambion Inc., An Applied Biosytems Business, US |
| - |
Nanoscale Aspects of Pharmaceutical Materials Y. Yang, P. Schields, L. Brostrom, P. Tishmack, R. McClurg, I. Ivanisevic, S. Bates, J-O. Henck, D. Engers, SSCI, An Aptuit Company, US |
| Back to Top |
|
Merck Innovation Symposium: siRNA Delivery | Exhibit Hall C |
| - |
Labile Catalytic Packaging and Delivering of Short Interference RNA to Cancer Cells: Control of Gold Nanoparticles “out” of RNA Complexes A.M. Chen, O. Taratula, D. Wei, T. Minko, H. He, Rutgers, The State of New Jersey, US |
| - |
In vitro transfection efficiency of chitosan nanoparticles for gene delivery M. Malhotra, A. Kulamarva, S. Sebak, J. Bhathena, S. Prakash, McGill University, CA |
| - |
Toward in vivo Targeting Delivery of siRNA for Efficient Cancer Therapy O. Taratula, P. Kirkpatrick, R. Salva, I. Pandya, T. Minko, H. He, Rutgers-Newark University, US |
| - |
SiRNA for Therapeutic Immuno-modulation: Simultaneous Delivery of Cytokine-targeted SiRNA and DNA Antigens to Dendritic Cells using Polymer Microcarriers A. Singh, H. Nie, B. Ghosn, K. Roy, The University of Texas at Austin, US |
| - |
Multilayered ABCD Nanoparticles for siRNA delivery M. Thanou, A. Miller, Imperial College London, UK |
| - |
Delivery systems for enhanced siRNA delivery A-L. Bolcato-Bellemin, M-E. Bonnet, J-P. Behr, P. Erbacher, Polyplus-transfection, FR |
| Back to Top |
|
Phage Nanobiotechnology | Exhibit Hall C |
| - |
Phage microarray K.A. Vaglenov, S.N. Ustinov, G.A. Kuzmicheva, V.A. Petrenko, Auburn University, US |
| - |
Modulating affinity of landscape phage nanoparticles by mutagenesis of the major coat protein G.A. Kuzmicheva, A.M. Eroshkin, V.A. Potemkin, V.A. Petrenko, Auburn University, US |
| - |
Landscape phage libraries as a source of bioselective nanomaterials G.A. Kuzmicheva, I.B. Sorokulova, P.K. Jayanna, V.A. Petrenko, Auburn University, US |
| - |
Directed Evolution of Bone Associated Protein Through Phage Display S.-W. Lee, University of California, Berkeley, US |
| - |
Engineering of bacteriophages displaying affinity tags on its head for biosensor applications M. Tolba, L.Y. Brovko and M.W. Griffiths, University of Guelph, CA |
| - |
Engineering hybrid nanostructures with phage particles L. Makowski, L. Chen, Argonne National Laboratory, US |
| - |
Landscape phage probes for PC3 prostate carcinoma cells P.K. Jayanna, P. Deinnocentes, R.C. Bird, V.A. Petrenko, Auburn University, US |
| - |
Landscape Phage Probes for Breast Cancer Cells O.A. Fagbohun, D. Bedi, P.K. Jayanna, P.A. Deinnocentes, R.C. Bird, V.A. Petrenko, Auburn University, US |
| - |
Unspecific uptake of M13-type bacteriophage into human endothelial cell lines. O.A. Mandrup, P. Kristensen, University of Aarhus, DK |
| - |
Phage engineering for neural tissue regeneration A.M. Merzlyak, S.W. Lee, UC Berkeley, US |
| - |
Genetically engineered M13 bacteriophages as standalone tethers for probing single-molecule protein-DNA interactions A.S. Khalil, J.Y. Mao, D. Ghosh, M.J. Lang, A.M. Belcher, Massachusetts Institute of Technology, US |
| - |
High speed Atomic Force Microscopy for imaging Cell-Virus interactions G.E. Fantner, D.S. Gray, I.W. Rangelow, A.M. Belcher, Massachusetts Institute of Technology, US |
| - |
Biotemplated synthesis of materials for photo-oxidation of water A. Magyar, S. Cui, Y-S Nam, V. Dini, A.M. Belcher, Massachusetts Institute of Technology, US |
| - |
Evolutionary selection of bone mineral hydroxyapatite binding peptide using landscape phage library S. Modali, G. Abbineni, P. Jayanna, V. Petrenko, C. Mao, University of Oklahoma, US |
| Back to Top |
| 3:30 |
Merck Innovation Symposium: siRNA Delivery | Room 208 |
| 3:30 |
Introduction: siRNA Delivery A. Sachs, Merck, US |
| 3:40 |
Development of a new RNAi therapeutics platform J. Kamens, W. Salomon, H. Baigude, J. McCarroll, C.-S. Yang, P. Swain, T. Rana, T. Woolf, D. Samarsky, P. Pavco, RXi Pharmaceutical, US |
| 4:00 |
Amphoteric liposomes are a platform for multi-organ delivery of oligonucleotides C. Reinsch, U. Rauchhaus, S. Panzner, novosom AG, DE |
| 4:20 |
Oral Delivery of Map4K4 siRNA to Macrophages Inhibits TNF alpha Production and Protects against a LPS-Galactosamine Challenge in Mice M. Aouadi, G. Tesz, E. Soto, M. Wang, S. Nicoloro, G. Ostroff, M. Czech, University of Massachusetts Medical School, US |
| 4:40 |
Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis, Calando Pharmaceuticals, US |
| 5:00 |
Targeting and Delivery of siRNA using Nanoparticles Fabricated via the PRINT Process D.A. Canelas, X. Gao, S. Tian, P.A. Ropp, J.M. DeSimone, University of North Carolina at Chapel Hill, US |
| 5:20 |
Long-Circulating Micelle-like DNA-encapsulating Nanoparticles for Systemic Gene Delivery Y.T. Ko, W.C.A. Kale, V.P. Torchilin, Northeastern University, US |
| 5:40 |
Efficient siRNA Delivery by Secondary and Tertiary Amine Modified Polysaccharides B. Ghosn, A. Singh, K. Roy, The University of Texas at Austin, US |
| | Wednesday June 4 |
| Back to Top |
| 8:30 |
Nanotechnology for Cancer Prevention, Diagnosis and Treatment | Room 210 |
| | Session chair: Vladimir Torchilin, Northeastern University, US |
| 8:30 |
Cancer Gene Therapy Using Nanoparticle Vectors J.A. Roth, Anderson Cancer Center, US |
| 9:15 |
Folate-Targeted Nanoparticle Therapies for Cancer P.S. Low, Purdue University and Endocyte Pharmaceuticals, US |
| Back to Top |
| 10:30 |
Nanotechnology for Cancer Prevention, Diagnosis and Treatment | Room 210 |
| | Session chair: Vladimir Torchilin, Northeastern University, US |
| 10:30 |
Clinical Translation of Nanotechnology for Cancer: The NCI Alliance’s Perspective P. Grodzinski, NCI/NIH, US |
| 11:00 |
Nanotechnology Applied to Clinical Biomarker Medicine L. Liotta, George Mason University, US |
| 11:30 |
Integrated Nanoplatforms for Cancer Detection S.R. Manalis, Massachusetts Institute of Technology, US |
| Back to Top |
| 1:30 |
Nanotechnology for Cancer Prevention, Diagnosis and Treatment | Room 210 |
| | Session chair: Vladimir Torchilin, Northeastern University, US |
| 1:30 |
Molecular Imaging in Cancer A. Moore, MGH/Harvard Medical School, US |
| 2:00 |
Magnetic Nanoparticles for Thermal Therapy J. Hoopes, Dartmouth Medical Center, Hanover, NH, US |
| 2:30 |
Nanocarriers for Tumor-Targeted Drug Delivery T. Minko, Rutgers, US |
| Back to Top |
| 3:30 |
Nanotechnology for Cancer Prevention, Diagnosis and Treatment | Room 210 |
| | Session chair: Vladimir Torchilin, Northeastern University, US |
| 3:30 |
Nanocell Delivery System for Combination Cancer Therapy M.N. Milton, Tempo Pharmaceuticals, US |
| 4:00 |
Multifunctional Nanocarriers for Cancer Therapy V. Torchilin, Northeastern University, US |
| | Thursday June 5 |
| Back to Top |
| 10:30 |
Drug and Gene Delivery Systems | Room 209 |
| | Session chair: Steve Xanthoudakis, Merck, US |
| 10:30 |
Cell-mediated, heat-based therapy for combating HIV infection H.T. Denver, C.M. de Noronha, D.-A. Borca-Tasciuc, Rensselaer Polytechnic Institute, US |
| 10:50 |
A broad-spectrum viricide and its application as a novel human anti-viral therapeutic system E. Seymour, A. Diwan, V. Boniuk, R. Barton, NanoViricides, Inc., US |
| 11:10 |
Gene Delivery and Transfection Studies with Lipopolyplexes in Human Endothelial and Smooth Muscle Cells L. Brito, S. Little, R. Langer, M. Amiji, Northeastern University, US |
| 11:30 |
A Micro-Implant based on MEMS (Micro-Electro-Mechanical-Sysems) Technology for Treatment of Hemorrhagic Shock in Ambulatory Settings N.M. Elman, H-L. Ho Duc, M.J. Cima, Massachusttes Institute of Technology, US |
| 11:50 |
Development of Peptide Nucleic Acid Assemblies for Application in Drug Delivery and Molecular Sensing F.N. Butler, O. Elibol, B.D. Hines, B. Reddy Jr., R. Bashir, D.E. Bergstrom, Purdue University, US |
| |
Welcome
NSTI is proud to collaborate with the National Cancer Institute (NCI) in presenting a
Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and
Treatment.
Towards the end of eliminating suffering and death from cancer, the
National Cancer Institute is engaged in efforts to harness the power of
nanotechnology to radically change the way we diagnose, image and treat
cancer. The NCI-NSTI Nanotechnology for Cancer Special Symposium will
run in parallel with the Nanotech 2008 and the BioNano 2008 providing a
unique multidisciplinary environment directed towards addressing the
challenges of cancer research and treatment.
Video Journey Into Nanotechnology
Watch
Video Journey Into Nanotechnology (provided courtesy of NCI)
Synopsis
Nanotechnology has the potential to have a revolutionary impact on
cancer diagnosis and therapy. It is universally accepted that early
detection of cancer is essential even before anatomic anomalies are
visible. A major challenge in cancer diagnosis in the 21st century is to
be able to determine the exact relationship between cancer biomarkers
and the clinical pathology, as well as, to be able to non-invasively
detect tumors at an early stage for maximum therapeutic benefit. For
breast cancer, for instance, the goal of molecular imaging is to be able
to accurately diagnose when the tumor mass has approximately 100-1000
cells, as opposed to the current techniques like mammography, which
require more than a million cells for accurate clinical diagnosis.
In cancer therapy, targeting and localized delivery are the key
challenges. To wage an effective war against cancer, we have to have the
ability to selectively attack the cancer cells, while saving the normal
tissue from excessive burdens of drug toxicity. However, because many
anticancer drugs are designed to simply kill cancer cells, often in a
semi-specific fashion, the distribution of anticancer drugs in healthy
organs or tissues is especially undesirable due to the potential for
severe side effects. Consequently, systemic application of these drugs
often causes severe side effects in other tissues (e.g. bone marrow
suppression, cardiomyopathy, neurotoxicity), which greatly limits the
maximal allowable dose of the drug. In addition, rapid elimination and
widespread distribution into non-targeted organs and tissues requires
the administration of a drug in large quantities, which is often not
economical and sometimes complicated due to non-specific toxicity. This
vicious cycle of large doses and the concurrent toxicity is a major
limitation of current cancer therapy. In many instances, it has been
observed that the patient succumbs to the ill effects of the drug
toxicity far earlier than the tumor burden.
This symposium will address the potential ways in which nanotechnology
can address these challenges. Distinguished speakers will summarize the
current state of the art and future barriers. Contributions are also
solicited in the following topics.
Topics and Applications
- Science and technologies for cancer diagnostic and imaging techniques using nanoparticles as reporter platforms and contrast enhancing agents;
- Bionalaytical nanotechnology for detection of biomarkers
- Nanoparticle platforms polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, magnetic nanoparticles, and self-assembling nanosystems;
- Synthetic chemistry required to design and optimize new strategies for nanoparticle preparation and functionalization;
- Therapeutic targeted and intra-cellular drug and gene delivery using nanocarriers;
- Nanoparticles for delivery of electromagnetic energy for hyperthermia and thermal ablation of tumors;
- Theoretical modeling of nanoparticle processes in biological and medical environments, and of drug and gene delivery;
- Combination therapies (drug and energy delivery) using nanoparticles
- Clinical diagnosis and therapy of prostate, breast, and liver cancer.
top
Journal Submissions
Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine)
Nanomedicine: Nanotechnology, Biology and Medicine
(Nanomedicine) is a newly established, international,
peer-reviewed journal published quarterly. Nanomedicine publishes basic,
clinical, and engineering research in the innovative field of
nanomedicine. Article categories include basic nanomedicine, diagnostic
nanomedicine, experimental nanomedicine, clinical nanomedicine, and
engineering nanomedicine, pharmacological nanomedicine.
For consideration into the Nanomedicine: Nanotechnology, Biology and
Medicine journal please select the “Submit to Nanomedicine:
Nanotechnology, Biology and Medicine” button during the on-line
submission procedure. You may only select a single journal during the
submission process.
Journal of Nanoparticle Research
Selected Nanotech Proceedings papers will be reviewed and invited into a
Special Issue of Journal of Nanoparticle Research.
The journal disseminates knowledge of the physical, chemical and
biological phenomena and processes in nanoscale structures.
For consideration into this Special Issue of Journal of Nanoparticle
Research, please select the “Submit to Journal of Nanoparticle Research”
button during the on-line submission procedure. You may only select a
single journal during the submission process.
top
|